CAMBRIDGE EPIGENETIX
Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX is pioneering the field of clinical epigenetics, and the company’s technology has proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. Research has revealed a wide range of diagnostic and prognostic applications for 5hmC, no... w one of the most important biomarkers in the quest to improve human health. Spun-out of the University of Cambridge in 2012, CEGX was founded to develop and commercialise the science of world leading researchers Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing, and Professor Anjana Rao, who identified the essential role of the TET enzymes and 5hmC in development and disease. A privately held company headquartered in Cambridge, UK, Cambridge Epigenetix is supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures, Ahren Innovation Capital, DNA Capital and the University of Cambridge.
CAMBRIDGE EPIGENETIX
Industry:
Biotechnology Health Care Health Diagnostics Medical
Founded:
2012-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.cambridge-epigenetix.com
Total Employee:
51+
Status:
Active
Contact:
+44 1223 800700
Email Addresses:
[email protected]
Total Funding:
155.19 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Foundation Medicine
Foundation medicine is a molecular information company developing clinical diagnostic tests that facilitates personalized cancer therapies.
Metabolomic Diagnostics
Metabolomic Diagnostics specializes in the development of novel biomarker based diagnostic solutions for complex diseases
Knopp Biosciences
Knopp Neurosciences is a drug discovery and development company working on treatments for neurological disorders.
Redcliffe Labs
Redcliffe is a one-stop diagnostic platform offering a wide selection of tests to choose from and delivering care closer to the customer.
xRapid
xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Current Advisors List
Current Employees Featured
Founder
Investors List
New Science Ventures
New Science Ventures investment in Series D - Cambridge Epigenetix
Temasek Holdings
Temasek Holdings investment in Series D - Cambridge Epigenetix
Third Point
Third Point investment in Series D - Cambridge Epigenetix
Sequoia Capital
Sequoia Capital investment in Series D - Cambridge Epigenetix
Ahren Innovation Capital
Ahren Innovation Capital investment in Series D - Cambridge Epigenetix
GV
GV investment in Series D - Cambridge Epigenetix
New Science Ventures
New Science Ventures investment in Series C - Cambridge Epigenetix
GV
GV investment in Series C - Cambridge Epigenetix
Ahren Innovation Capital
Ahren Innovation Capital investment in Series C - Cambridge Epigenetix
DNA Capital
DNA Capital investment in Series C - Cambridge Epigenetix
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-14 | Cambridge Epigenetix Names Peter Fromen as Chief Executive Officer |
Official Site Inspections
http://www.cambridge-epigenetix.com Semrush global rank: 5 M Semrush visits lastest month: 1.68 K
- Host name: 83.0.153.160.host.secureserver.net
- IP address: 160.153.0.83
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Cambridge Epigenetix"
Cambridge Epigenetix - Crunchbase Company Profile …
Cambridge Epigenetix aims to change the way medicine is practiced by reducing several routine and important diagnostic screening and detection tests for colorectal cancer and other common tumours to a simple blood draw. CEGX …See details»
Cambridge Epigenetix - Org chart - The Org
Explore Cambridge Epigenetix's organizational chart. Discover current team members including executives, board members, and advisors. ... Get your company on The Org for free, joining over 140,000 top organizations. Add …See details»
Cambridge Epigenetix - Org Chart, Teams, Culture & Jobs - The Org
Cambridge Epigenetix (CEGX) is a life sciences tools and analytics company that has created a technology platform delivering step changes in both the type of information that can be …See details»
Chief Executive Officer at Cambridge Epigenetix - The Org
Here, they transformed the commercial organization, leading the global commercial team to achieve record levels of sales, growing revenue by 65% and more than doubling the …See details»
Cambridge Epigenetix - Funding, Financials, Valuation & Investors
Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.See details»
Cambridge Epigenetix - Craft
Cambridge Epigenetix (also known as CEGX) is a bioscience company that uses epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood …See details»
Cambridge Epigenetix - Contacts, Employees, Board Members
Cambridge Epigenetix has 4 board members and advisors, including Roelof Botha. Roelof Botha Board Member Dec 2015. Bobby Yerramilli-Rao Board Member Apr 2012. Nick McCooke …See details»
The next Cambridge game-changer: Epigenetix
Dec 2, 2016 One of Cambridge Enterprise’s most exciting new portfolio companies is Cambridge Epigenetix, a pioneer in the development of epigenetic sequencing.Founded in 2012 by Prof Shankar Balasubramanian of the …See details»
Cambridge Epigenetix | Collaboration and Impact
Cambridge Epigenetix has undergone three successful rounds of venture capital funding, which has allowed the company to further develop a range of tools for epigenetic analysis. Currently …See details»
Cambridge Epigenetix - VentureRadar
Cambridge Epigenetix aims to change the way medicine is practised by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of the 5 …See details»
Cambridge Epigenetix Raises $88 Million Series D …
Nov 3, 2021 Professor Sir Shankar Balasubramanian FRS, founder of Cambridge Epigenetix, said, “We are pleased to have raised a significant Series D round from high-profile investors to support the commercial launch of the …See details»
☑️Cambridge Epigenetix — Consulting Organization from UK, …
Cambridge Epigenetix — Consulting Organization from UK, has experience with Horizon 2020 (2014 - 2020), it`s involved in Health, Laboratory & Measurement sectors.See details»
Cambridge Epigenetix Names Peter Fromen as Chief Executive …
Jun 3, 2022 CAMBRIDGE, United Kingdom, June 14, 2022 — Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is revolutionizing genome sequencing, …See details»
Cambridge Epigenetix - Biotech Careers
Cambridge Epigenetix has developed state-of-the-art technology to enable accurate quantification of 5mC and 5hmC in parallel at single-base resolution, something that is not possible with …See details»
Cambridge Epigenetix Raises $88 Million Series D Financing to …
Nov 2, 2021 CAMBRIDGE, United Kingdom, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome …See details»
Cambridge Epigenetix Names Peter Fromen as Chief Executive …
Dec 13, 2021 CAMBRIDGE, United Kingdom, June 14, 2022 (GLOBE NEWSWIRE) -- Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is …See details»
Cambridge Epigenetix Raises $88 Million Series D Financing to
Feb 11, 2021 CAMBRIDGE, United Kingdom, Nov. 02, 2021 -- Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, today …See details»
Cambridge Epigenetix Names Peter Fromen as Chief Executive
Jun 14, 2022 CAMBRIDGE, United Kingdom, June 14, 2022 (GLOBE NEWSWIRE) -- Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is …See details»
Cambridge Epigenetix Names Peter Fromen as Chief Executive …
Jun 14, 2022 CAMBRIDGE, United Kingdom, June 14, 2022 (GLOBE NEWSWIRE) -- Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is …See details»
Cambridge Epigenetix Raises $88 Million Series D Financing
Nov 2, 2021 Cambridge Epigenetix is revolutionizing sequencing by delivering new dimensions of information from DNA to see and treat disease earlier and transform life sciences and …See details»